Atherosclerosis Risk in Communities Study (ARIC)

在过去的20年里，社区动脉粥样硬化风险(ARIC)研究为动脉粥样硬化及其进展的风险因素、冠心病和中风的风险因素以及社区心血管疾病发病率的趋势提供了重要的新信息。在此，我们建议ARIC从2005年继续到2012年。每个ARIC现场中心、协调中心和实验室都有单独的提案。 我们针对ARIC RFP进行更新的目标是： 1.在四个ARIC社区完成了长达23年的冠心病(CHD)监测，从而能够检测特定种族群体的CHD发病率、病死率和死亡率的趋势。在2005-2009年，CHD监测将扩大到75-84岁的老年人，并将进行住院心力衰竭(55岁及以上)和门诊心力衰竭(65岁及以上)的监测。 2.对ARIC以前检查的心血管疾病(CVD)发病率和死亡率队列进行了23年的跟踪，以确定与发生CHD、中风和2005-2009年心力衰竭相关的因素。 3.利用储存的血液、尿液和DNA样本，从现有的亚临床疾病病例、现有的和新发生的心血管疾病病例和对照对象，以及亚临床疾病快速发展的亚组中，识别和表征新的心血管疾病遗传和生化危险因素。要测量的基因和分析物将通过动脉粥样硬化和心血管疾病的途径进行鉴定。 延期将使ARIC能够继续(1)解决心血管疾病的社区趋势，(2)利用其宝贵的数据库和生物样本资源来解决心血管疾病病因的新问题。 合作研究协调中心一直作为ARIC协调中心(CC)，并将继续为ARIC研究提供总体运作和科学协调，特别强调统计方法。CC工作人员将参加所有ARIC委员会和小组委员会，协调电话会议并记录会议记录。CC工作人员将作为主要作者和合著者积极参与手稿的撰写，并在需要时提供统计咨询、分析和审查。CC将维护并参与手册、表格和说明的开发。培训课程将由CC工作人员协调。将维护和创建数据管理，包括数据输入系统和为分析准备数据文件的系统，以及冠心病和心力衰竭的死亡率和发病率分类。所有MMCC活动将由CC协调。将编写质量控制报告，并对外地中心和中央机构进行监测访问。当问题出现时，协调委员会将对社区监测(CHD和HF)、AFU和实验室研究(包括病例队列研究)的需求做出回应。CC将维护和更新ARIC的两个网站。协调委员会将协调ARIC向ARIC科学家内外的调查人员传播数据的努力。

Over the past 20 years, the Atherosclerosis Risk In Communities (ARIC) Study has provided important new information on risk factors for atherosclerosis and its progression, on risk factors for coronary heart disease and stroke, and on trends in community rates of cardiovascular disease. We herein propose continuation of ARIC from 2005 to 2012. There are separate proposals for each ARIC Field Center, the Coordinating Center, and the Laboratories. Our aims for renewal in response to the ARIC RFPs are: 1. Completion of 23 years of coronary heart disease (CHD) surveillance in the four ARIC communities, permitting detection of trends in CHD Incidence, case fatality, and mortality in racesex-specific subgroups. For 2005-2009, CHD Surveillance will expand to 75-84 year olds, and inpatient heart failure (55 years and older) and outpatient heart failure surveillance (65 years and older) will be undertaken. 2. Follow-up of ARIC's previously examined cohort for cardiovascular disease (CVD) morbidity and mortality over 23 years, to identify factors related to Incident CHD, stroke, and for 2005-2009, heart failure. 3. Identification and characterization of novel genetic and biochemical risk factors for CVD using stored blood, urine, and DNA samples from available subclinical disease cases, available and newly-occurring CVD cases and control subjects, and subgroups with rapid progression of subclinical disease. The genes and analytes to be measured will be identified via a pathway approach to atherosclerosis and CVD. An extension will enable ARIC to continue to (1) address community trends in CVD and (2) make use of its valuable database and biosample resource to address new questions on the etiology of cardiovascular disease. The Collaborative Studies Coordinating Center has served as the ARIC coordinating center (CC) and will continue providing the overall operation and scientific coordination for the ARIC study with special emphasis on statistical methodology. CC staff will participate in all the ARIC committees and subcommittees, will coordinate conference calls and take minutes. The CC staff will actively participate in writing manuscripts as lead and co-authors and provide statistical advice, analyses and review when needed. The CC will maintain and participate in development of manuals, forms, and instructions. Training sessions will be coordinated by CC staff. Data management, including systems for data entry and systems to prepare data files for analyses, will be maintained and created for HF and mortality and morbidity classification (MMCC) for CHD and HF. All MMCC activities will be coordinated by CC. Quality control reports will be prepared and monitoring visits to field centers and central agencies will be on going. The CC will respond to needs of community surveillance (CHD and HF), AFU, and laboratory studies (including case-cohort studies) as issues arise. The CC will maintain and update two websites for ARIC. The CC will coordinate ARIC's efforts to disseminate data to investigators within and outside the ARIC scientists.